Page 2,821«..1020..2,8202,8212,8222,823..2,8302,840..»

Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs

Posted: March 6, 2012 at 4:51 pm

Public release date: 6-Mar-2012 [ | E-mail | Share ]

Contact: Cody Mooneyhan cmooneyhan@faseb.org 301-634-7104 Federation of American Societies for Experimental Biology

Bethesda, MDA new research discovery by a team of Stanford and European scientists offers hope that people with atherosclerotic disease may one day be able to avoid limb amputation related to ischemia. A new research report appearing online in the FASEB Journal suggests that the delivery of genes for two molecules naturally produced by the body, called "PDGF-BB" and "VEGF" may successfully cause the body to grow new blood vessels that can save ischemic limbs.

"We hope that our findings will ultimately develop into a safe and effective therapy for the many patients, suffering from blocked arteries in the limbs, who are currently not adequately treated by surgery or drugs," said Helen M. Blau, Ph.D., a senior researcher involved in the work and Associate Editor of the FASEB Journal from the Baxter Laboratory for Stem Cell Biology at the Institute for Regenerative Medicine and Stem Cell Biology at Stanford. "This could help avoid the devastating consequences of limb amputations for both patients and their families."

To make this discovery, Blau and colleagues, including Andrea Banfi (now at Basel University), introduced the genes for PDGF-BB and VEGF into the muscles of mice, either independently or together. When high doses of VEGF alone were produced, they caused the growth of vascular tumors. When the two factors were produced in unbalanced amounts, tumor growth also occurred. When VEGF and PDGF were delivered in a fixed ratio relative to one another, however, no tumors occurred, and blood flow was restored to ischemic muscle tissue and damage repaired without any toxic effects. To achieve a "balanced" delivery of PDGF-BB and VEGF, scientists placed both genes in a single gene therapy delivery mechanism, called a "vector."

Although the report shows the feasibility of growing robust and safe new blood vessels that restore blood flow to diseased tissues, Blau points out that "there are multiple challenges to correcting peripheral vasculature disease by using proangiogenic gene therapy strategies. Two important challenges are what to deliver and how to get it to where it can have beneficial effects. Clinical success will require both delivering a gene therapy construct that encodes for effective angiogenic factors and ensuring that the sites of delivery are where the construct can have the greatest clinical benefit."

"This ingenious work, based on the latest techniques of molecular biology, tells us that it is possible to reinvigorate parts of our body that can't get enough blood to keep them going," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "The next question is whether this approach will work in humans and exactly how to deliver the new treatment to places that need it the most."

###

Receive monthly highlights from the FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB) and is the most cited biology journal worldwide according to the Institute for Scientific Information. In 2010, the journal was recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century. FASEB is composed of 26 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. Celebrating 100 Years of Advancing the Life Sciences in 2012, FASEB is rededicating its efforts to advance health and well-being by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.

Details: Andrea Banfi, Georges von Degenfeld, Roberto Gianni-Barrera, Silvia Reginato, Milton J. Merchant, Donald M. McDonald, and Helen M. Blau. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. FASEB J. doi:10.1096/fj.11-197400 ; http://www.fasebj.org/content/early/2012/03/05/fj.11-197400.abstract

See the original post here:
Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs

Posted in Gene therapy | Comments Off on Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs

Nuvilex Forecasts Vast Partnership Opportunities Using Breakthrough Stem Cell Technology

Posted: March 6, 2012 at 4:51 pm

SILVER SPRING, Md.--(BUSINESS WIRE)--

Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today pointed out the potential for substantial partnership and licensing opportunities using the companys cell encapsulation technology for applications in stem cell research and medicine. Migration of implanted cells away from the target site and host rejection have been recognized as fundamental challenges faced by the stem cell community regarding their use in therapy, which the companys technology overcomes.

The technology being acquired from associate SG Austria is used to place live stem cells into strong, flexible and permeable capsules. These capsules can then be implanted into animals or humans for specific therapies. Stem cells can then exist at the desired location inside the capsules, prevented from migrating and protected from the immune system that aims to eliminate such foreign cells from the body.

Stem cell therapy is being used by clinicians throughout the world for treating such diverse diseases as spinal cord injury, amyotrophic lateral sclerosis, burns, glioma, multiple myeloma, arthritis, heart disease, stroke, Stargardt's Macular Dystrophy, and age-related macular degeneration, among others, most of which can be found at ClinicalTrials.gov.

Historically, researchers have faced numerous difficulties in succeeding with certain stem cell treatments, because of the problems associated with keeping stem cells alive for significant periods of time, stopping rejection and destruction by the recipients immune system, and keeping stem cells from migrating away from the desired sites. Cells encapsulated in SG Austrias porous beads have been shown to remain alive for long periods of time in humans, surviving intact for at least two years. Once encapsulated, cells are protected from the bodys immune system. Furthermore, encapsulated cells remain within the beads and are unable to migrate to other sites in the body.

In the February 29, 2012 research report, Goldman Small Cap Research stated, The Cell-in-a-Box approach could significantly advance the implementation and utilization of stem cells for a host of debilitating diseases and conditions, making it a uniquely valuable commodity. We believe that by partnering with leading players in the field, Nuvilex could find that companies with deep pockets would be happy to collaborate or license the delivery system and engage in further research which could result in meaningful development and licensing revenue.

Dr. Robert Ryan, Chief Executive Officer of Nuvilex, discussed the value for licensing the companys stem cell therapy, adding, By overcoming traditional barriers to effective stem cell therapy, namely viability, migration, and host rejection, we believe these new advances in medical science utilizing stem cells and encapsulation will enable us to take quantum leaps forward now and in the future. As a result of challenges SG Austria has overcome, new advances will be surprisingly close at hand and are part of the driving force behind our desire to work with a number of companies in this endeavor. Our primary goal has been and remains to use our technology to bring life changing treatments to patients on an expedited basis.

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of clinically useful therapeutic live encapsulated cells and services for encapsulating live cells for the research and medical communities. Through our effort, all aspects of our corporate activities alone, and especially in concert with SG Austria, are rapidly moving toward completion, including closing our agreement. One of our planned offerings will include cancer treatments using the companys industry-leading live-cell encapsulation technology.

Safe Harbor Statement

Continued here:
Nuvilex Forecasts Vast Partnership Opportunities Using Breakthrough Stem Cell Technology

Posted in Stem Cell Therapy | Comments Off on Nuvilex Forecasts Vast Partnership Opportunities Using Breakthrough Stem Cell Technology

BioTime and Aastrom Biosciences — Stem Cell Research Making Breakthroughs

Posted: March 6, 2012 at 5:41 am

NEW YORK, NY--(Marketwire -03/05/12)- February was a challenging month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over the last month -- underperforming the S&P 500 by close to 17 percent over that time frame. Despite the drop in investor optimism, new and promising research continues to propel the industry forward. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on BioTime, Inc. (AMEX: BTX - News) and Aastrom Biosciences, Inc. (NASDAQ: ASTM - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/BTX

http://www.fivestarequities.com/ASTM

A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. "This has never been accomplished before, despite a decade of cell therapy trials for patients with heart attacks. Now we have done it," Eduardo Marban, director of the Cedars-Sinai Heart Institute and one of the study's co-authors, said in a statement. "The effects are substantial."

In another study, researchers led by Jonathan Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital, argue they've discovered the ovaries of young women harbor very rare stem cells capable of producing new eggs.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases.

BioTime, Inc. primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. The company recently elected to market progenitors of muscle stem cells bearing hereditary diseases. BioTime will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI) of Chicago, Illinois.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

Visit link:
BioTime and Aastrom Biosciences -- Stem Cell Research Making Breakthroughs

Posted in Cell Therapy | Comments Off on BioTime and Aastrom Biosciences — Stem Cell Research Making Breakthroughs

Stem Cells Make Human Eggs: Cure for Infertility? – Video

Posted: March 5, 2012 at 9:39 pm

27-02-2012 20:17 BY EMILY SPAIN You're watching multisource health/science news analysis from Newsy. Researchers might have a cure in the works for infertility in women. Scientists say they found ovary stem cells they can convert into unfertilized human eggs. WBAL has the details of the experiment. "Similar experiments in mice show transplanting the egg cells into the ovaries of infertile females produced healthy offspring. Scientists believe the same is possible in humans and are exploring the possibility of human stem cell banks." Researchers from Massachusetts General Hospital used a cell-sorting machine to find reproductive cells from the ovaries of mice and then did the same with donated human ovaries. According to the New York Times, the experiment on human ovaries had positive results. "The egg cells, when injected into mice, generated follicles, the ovarian structure in which eggs are formed, as well as mature eggs, some of which had a single set of chromosomes, a signature of eggs and sperm." The BBC talked to one doctor who called the results of the experiment "extremely significant" and "a potentially landmark piece of research." The outlet quoted him saying: "If this research is confirmed it may overturn one of the great asymmetries of reproductive biology - that a woman's reproductive pool of gametes may be renewable, just like a man's." Other researchers aren't so sure. Some question if egg-producing cells actually exist in ovaries. Director of the Center for Reproductive ...

The rest is here:
Stem Cells Make Human Eggs: Cure for Infertility? - Video

Posted in Stem Cell Videos | Comments Off on Stem Cells Make Human Eggs: Cure for Infertility? – Video

Personal Health: Chemo brain, stem cells and more

Posted: March 5, 2012 at 9:39 pm

Study: 'Chemo brain' may not go away for cancer patients

Chemotherapy patients have long complained of the mental fog that tends to accompany treatment. Now, a new study suggests that certain combinations of chemo drugs may have long-term effects on cognition.

Researchers looked at 196 women who had been treated for early-stage breast cancer with a three-drug chemotherapy regimen. The women underwent cognition testing an average of 21 years after they had received chemo. They were compared with 1,509 healthy women who had never had cancer. The women in the study ranged in age from 50 to 80.

The women who had chemotherapy fared much worse than the control group on tests of verbal memory, cognitive processing speed, executive function, and psychomotor speed.

Previous studies suggested that "chemo brain" can persist for five years after treatment, but this study is the first to show possible permanent cognitive damage.

- Los Angeles Times

More Americans are turning to the emergency room for routine dental problems - a choice that often costs 10 times more than preventive care and offers far fewer treatment options than a dentist's office, according to an analysis of government data and dental research.

Most of those emergency visits involve trouble such as toothaches that could have been avoided with regular checkups but went untreated, in many cases because of a shortage of dentists, particularly those willing to treat Medicaid patients, the analysis said.

The number of E.R. visits nationwide for dental problems increased 16 percent from 2006 to 2009, and the report released Tuesday by the Pew Center on the States suggests the trend is continuing.

Emergency rooms generally can offer pain relief and medicine for infected gums but not much more for dental patients. And many patients are unable to find or afford follow-up treatment, so they end up back in the emergency room.

Continue reading here:
Personal Health: Chemo brain, stem cells and more

Posted in Stem Cell Videos | Comments Off on Personal Health: Chemo brain, stem cells and more

Stem cells can repair a damaged cornea

Posted: March 5, 2012 at 9:39 pm

Public release date: 5-Mar-2012 [ | E-mail | Share ]

Contact: Charles Hanson charles.hanson@obgyn.gu.se 46-313-423-572 University of Gothenburg

A new cornea may be the only way to prevent a patient going blind but there is a shortage of donated corneas and the queue for transplantation is long. Scientists at the Sahlgrenska Academy at the University of Gothenburg, Sweden, have for the first time successfully cultivated stem cells on human corneas, which may in the long term remove the need for donators.

Approximately 500 corneal transplantations are carried out each year in Sweden, and about 100,000 in the world. The damaged and cloudy cornea that is turning the patient blind is replaced with a healthy, transparent one. But the procedure requires a donated cornea, and there is a severe shortage of donated material. This is particularly the case throughout the world, where religious or political views often hinder the use of donated material.

Replacing donated corneas

Scientists at the Sahlgrenska Academy, University of Gothenburg, have taken the first step towards replacing donated corneas with corneas cultivated from stem cells. Scientists Charles Hanson and Ulf Stenevi have used defective corneas obtained from the ophthalmology clinic at Sahlgrenska University Hospital in Mlndal. Their study is now published in the journal Acta Ophthalmologica, and shows how human stem cells can be caused to develop into what are known as "epithelial cells" after 16 days' culture in the laboratory and a further 6 days' culture on a cornea. It is the epithelial cells that maintain the transparency of the cornea.

First time ever on human corneas

"Similar experiments have been carried out on animals, but this is the first time that stem cells have been grown on damaged human corneas. It means that we have taken the first step towards being able to use stem cells to treat damaged corneas", says Charles Hanson. "If we can establish a routine method for this, the availability of material for patients who need a new cornea will be essentially unlimited. Both the surgical procedures and the aftercare will also become much more simple", says Ulf Stenevi.

Few clinics conduct transplants

Only a few clinics are currently able to transplant corneas. Many of the transplantations in Sweden are carried out at the ophthalmology clinic at Sahlgrenska University Hospital, Department of Ophthalmology, Mlndal.

View original post here:
Stem cells can repair a damaged cornea

Posted in Stem Cell Videos | Comments Off on Stem cells can repair a damaged cornea

ETX mom hopes 'Joel's Journey for Sight' leads to China

Posted: March 5, 2012 at 9:38 pm

TYLER, TX (KLTV) -

A young Tyler mom is doing everything she can to get her young son to China for stem cell treatments -- and she needs your help.

Emily Roberts's son, Joel Hilton, was born with two conditions that have left him blind and unable to grow properly.

He was born with optic nerve hypoplasia and septo-optic dysplasia, conditions that affect his sight and his pituitary gland, which affect his growth and development.

"I just, I never -- I mean, everyone says this -- never thought it would be me. I mean, you don't expect me, especially at 18 years old, I did not expect to have a blind child. It's just, why me," Roberts said. "But it happened. And he's here."

Now, Roberts's hope is to raise enough money to take Joel to China. A hospital there has accepted Joel to receive five umbilical cord stem cell treatments, which Roberts hopes will help Joel regain some sight and help restore some of his pituitary gland.

"It's not a 100 percent thing. I don't want people thinking that he's going to go and come back and be able to see 20/20. No. Even if he can see a little bit or know when the light's on or the light's off, or if he can see shadows and movement, that would be a miracle, because right now he can't see anything," Roberts said.

Joel receives physical, occupational, and early childhood therapies twice a week, but Roberts is the first to admit that life with these conditions has been very different than she'd imagined.

"He's definitely not like a normal child. Normal kids run around and he sits right here with mommy," Roberts said. "I have to carry him everywhere, he can't walk. I mean, he can't talk, either. I just kind of have to know. I know him pretty well, though, because we're always together. He's like my little buddy."

And her hope for Joel is for improvement of any kind after the stem cell treatment.

See original here:
ETX mom hopes 'Joel's Journey for Sight' leads to China

Posted in Stem Cell Treatments | Comments Off on ETX mom hopes 'Joel's Journey for Sight' leads to China

New Stem Cell Research Shows Promising Results — Advanced Cell Tech and NeoStem Poised to Benefit

Posted: March 5, 2012 at 9:38 pm

NEW YORK, NY--(Marketwire -03/05/12)- February was a challenging month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has slipped nearly 13 percent over the last month -- underperforming the S&P 500 by close to 17 percent over that time frame. Despite the drop in investor optimism, new research continues to propel the industry forward. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology, Inc. (OTC.BB: ACTC.OB - News) and NeoStem, Inc. (AMEX: NBS - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/ACTC

http://www.fivestarequities.com/NBS

A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. "This has never been accomplished before, despite a decade of cell therapy trials for patients with heart attacks. Now we have done it," Eduardo Marban, director of the Cedars-Sinai Heart Institute and one of the study's co-authors, said in a statement. "The effects are substantial."

In another study, researchers led by Jonathan Tilly, director of the Vincent Center for Reproductive Biology at Massachusetts General Hospital, argue they've discovered the ovaries of young women harbor very rare stem cells capable of producing new eggs.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The Company recently issued a press release stating that it utilized $13.6 million in cash for operations during 2011, compared to $8.8 million in the year-earlier period. The increase in cash utilization resulted primarily from ACT's ongoing clinical activities in the US and Europe.

NeoStem, Inc., a biopharmaceutical company, engages in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States and China. In January, Amorcyte, LLC, a NeoStem, Inc. company, announced the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

See more here:
New Stem Cell Research Shows Promising Results -- Advanced Cell Tech and NeoStem Poised to Benefit

Posted in Stem Cell Research | Comments Off on New Stem Cell Research Shows Promising Results — Advanced Cell Tech and NeoStem Poised to Benefit

VistaGen Therapeutics and Duke University Enter Into Strategic Research Collaboration

Posted: March 5, 2012 at 9:38 pm

SOUTH SAN FRANCISCO, CA--(Marketwire -03/05/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB - News) (OTCQB: VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue, and Duke University, one of the country's premier academic research institutions, have entered into a strategic research collaboration aimed at combining their complementary expertise at the forefront of cardiac stem cell technology, electrophysiology and tissue engineering. The initial goal of the collaboration is to explore potential development of novel, engineered, stem cell-derived cardiac tissues to expand the scope of VistaGen's drug rescue capabilities focused on heart toxicity. The research will be led at Duke, by Dr. Nenad Bursac, Associate Professor in the Departments of Cardiology and Biomedical Engineering, and at VistaGen, by Dr. Ralph Snodgrass, President and Chief Scientific Officer.

"We are pleased to be collaborating with Dr. Bursac and his team at Duke," said Dr. Snodgrass. "Our human stem cell-derived heart cells combined with Dr. Bursac's cutting-edge technology relating to cardiac electrophysiology and cardiac tissue engineering will permit us to use micro-patterned cardiac tissue to significantly expand the approaches we use in our Drug Rescue Programs to quantify drug effects on functional human cardiac tissue -- in effect, synthetic human heart muscle."

Dr. Bursac is a leader in the field of cardiac tissue engineering and cell-based therapies in which different cells, either alone or in combination with therapeutic molecules or biomaterials, can be transplanted into the human body to restore function of damaged or diseased organs. Dr. Bursac's research has additional applications in the fields of cardiac electrophysiology, in vitro drug screening, and the generation of novel bioengineered model systems for studies of heart development, function, and disease.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories after substantial development due to heart toxicity. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen's small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson's disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen's stem cell technology-based drug rescue activities, ongoing AV-101 clinical studies, its ability to enter into drug rescue collaborations and/or licensing arrangements with respect to one or more drug rescue variants, risks and uncertainties relating to the availability of substantial additional capital to support VistaGen's research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to AV-101 and any drug rescue variant identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at http://www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

More:
VistaGen Therapeutics and Duke University Enter Into Strategic Research Collaboration

Posted in Stem Cell Research | Comments Off on VistaGen Therapeutics and Duke University Enter Into Strategic Research Collaboration

Nuvilex Announces Major Breakthrough in Stem Cell Research

Posted: March 5, 2012 at 9:38 pm

SILVER SPRING, Md.--(BUSINESS WIRE)--

Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, released information today about the companys cell encapsulation technology and the breakthrough in stem cell research which overcomes specific fundamental challenges faced in stem cell therapyhost rejection and migration of implanted cells away from the target site.

Stem cell therapy is believed by many medical researchers as holding a key to treating cancer, Type 1 diabetes mellitus, Parkinson's disease, Huntington's disease, Celiac Disease, cardiac failure, muscle damage, neurological disorders, and other chronic, debilitating diseases. There are presently >1,400 registered trials using stem cells that are recruiting patients (ClinicalTrials.gov). The encapsulation technology being advanced allows live stem cells to be implanted into robust, flexible and permeable capsules where they can replicate inside the capsules at the target site free from attack by the bodys immune system and free to undergo natural changes to become the appropriate cell type needed.

The Goldman Small Cap Research report, issued February 29, 2012, noted some inherent difficulties encountered in stem cell treatments, such as keeping stem cells alive for significant periods of time, potential rejection of the cells and subsequent destruction by the recipients immune system, and the migration of the stem cells away from the critical treatment site, while making a distinction that the Companys cell encapsulation technology overcomes these concerns.

The report also accurately recognized, Cells encapsulated in SG Austrias porous beads remain alive for long periods of time in humans, surviving intact for at least two years. Once encapsulated, cells are protected from the bodys immune system. Furthermore, encapsulated cells remain within the beads and do not migrate out of the beads to other sites in the body.

In assessing the overall importance of this technology to Nuvilexs overall business model, Goldman pointed out, The Companys acquisition of the Cell-in-a-Box approach along with the expertise of SG Austria could significantly advance the implementation and utilization of stem cells for a host of debilitating diseases and conditions, in addition to being used to target cancer cells, thus making it a uniquely valuable commodity. We believe that by partnering with leading players in the field, Nuvilex could find that companies with deep pockets would be happy to collaborate or license the delivery system and engage in further research which could result in meaningful development and licensing revenue.

Dr. Robert Ryan, Chief Executive Officer of Nuvilex, added, There is a broad range of expanding research supporting the use of stem cells to treat a variety of human diseases and conditions. Our technology allows for precise maintenance and localization of stem cells, preventing their loss from the critical area of need, that will enable us to potentially create miniature organs at specific sites and as a result we believe greater utilization of those stem cells at the site for their intended purpose, once implanted. As stem cell treatments advance, we expect Nuvilex to be at the forefront of developing new, significant, life changing therapies.

For a detailed review of the research report and valuation methodology, investors are directed to the Goldman Research Report.

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of clinically useful therapeutic live encapsulated cells and services for encapsulating live cells for the research and medical communities. Through our effort, all aspects of our corporate activities alone, and especially in concert with SG Austria, are rapidly moving toward completion, including closing our agreement. One of our planned offerings will include cancer treatments using the companys industry-leading live-cell encapsulation technology.

Read more from the original source:
Nuvilex Announces Major Breakthrough in Stem Cell Research

Posted in Stem Cell Research | Comments Off on Nuvilex Announces Major Breakthrough in Stem Cell Research

Page 2,821«..1020..2,8202,8212,8222,823..2,8302,840..»